Brazilian Journal of Pain
https://brjp.org.br/article/doi/10.5935/2595-0118.20230076-en
Brazilian Journal of Pain
Case Report

Effect of prolonged-release tapentadol in the management of moderate-to-severe chronic pain in elderly patients. Case reports

Efeito do tapentadol de liberação prolongada no manejo da dor crônica de moderada a intensa em pacientes idosos. Relato de casos

Diogo Kallas Barcellos; João Marcos Rizzo; Fânia Cristina dos Santos

Downloads: 0
Views: 47

Abstract

BACKGROUND AND OBJECTIVES: Prolonged-release (PR) tapentadol has demonstrated efficacy, safety, and good tolerability for the management of moderate to severe chronic pain in patients over 65 years of age. The objective of this study was to describe three clinical cases in which tapentadol PR was used as treatment of moderate to severe chronic pain in individuals aged 75 to 83 years old.
CASE REPORT: Two female patients (75 and 83 years old) and one male patient (78 years old) with chronic osteoarticular pain or low back pain of moderate to severe intensities and with functional limitation, who had undergone previous unsuccessful treatments and were functionally limited, underwent treatment with tapentadol PR. Tapentadol PR was associated with considerable improvement of pain in all three patients, leading to greater independence in performing daily activities. In addition, the use of tapentadol PR did not cause any significant adverse effects.
CONCLUSION: Treatment with tapentadol PR seems to be effective and tolerable in the management of moderate to severe chronic pain in senior patients.

Keywords

Analgesia, Chronic pain, Elderly, Tapentadol

Resumo

JUSTIFICATIVA E OBJETIVOS: O tapentadol de liberação prolongada (LP) demonstrou eficácia, segurança e boa tolerabilidade para o tratamento de dor crônica moderada a grave em pacientes com mais de 65 anos de idade. O objetivo deste estudo foi descrever três casos clínicos em que o tapentadol de liberação prolongada foi usado como tratamento para dor crônica de moderada a grave em indivíduos de 75 a 83 anos de idade. 
RELATO DOS CASOS: Dois pacientes do sexo feminino (75 e 83 anos de idade) e um paciente do sexo masculino (78 anos de idade) com dor osteoarticular crônica ou dor lombar de intensidade moderada a intensa e com limitação funcional, que haviam sido submetidos a tratamentos anteriores sem sucesso e estavam limitados funcionalmente, foram submetidos a tratamento com tapentadol LP. O tapentadol LP foi associado a uma melhora considerável da dor em todos os três pacientes, levando a uma maior independência na realização das atividades diárias. Além disso, o uso do tapentadol LP não causou nenhum efeito adverso significativo. 
CONCLUSÃO: O tratamento com tapentadol parece ser eficaz e tolerável no tratamento da dor crônica moderada a grave em pacientes idosos.

Palavras-chave

Analgesia, Dor crônica, Idosos, Tapentadol

References

1 Ferretti F, Silva MR, Pegoraro F, Baldo JE, Sá CA. Dor crônica em idosos, fatores associados e relação com o nível e volume de atividade física. BrJP. 2019;2(1):3-7.

2 Dellaroza MS, Pimenta CA, Matsuo T. Prevalence and characterization of chronic pain among the elderly living in the community]. Cad Saude Publica. 2007;23(5):1151-60.

3 Dueñas M, Ojeda B, Salazar A, Mico JA, Failde I. A review of chronic pain impact on patients, their social environment and the health care system. J Pain Res. 2016;9:457-67.

4 Kalso E, Edwards JE, Moore AR, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372-80.

5 Ali A, Arif AW, Bhan C, Kumar D, Malik MB, Sayyed Z, Akhtar KH, Ahmad MQ. Managing chronic pain in the elderly: an overview of the recent therapeutic advancements. Cureus. 2018;10(9):e3293.

6 Kress HG. Tapentadol and its two mechanisms of action: Is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain. 2010;14(8):781-3.

7 Schwittay A, Sohns M, Heckes B, Elling C. Tapentadol prolonged release for severe chronic osteoarthritis pain in the elderly-a subgroup analysis of routine clinical practice data. Pain Res Manag. 2020;2020:5759265.

8 Mateos RG, Bernal DS, Morera LMT, Ferri CM, Escobar AE. Long-term effectiveness and tolerability of pain treatment with tapentadol prolonged release. Pain Physician. 2021;24(1):E75-85.

9 Freo U, Furnari M, Ambrosio F, Navalesi P. Efficacy and tolerability of tapentadol for the treatment of chronic low back pain in elderly patients. Aging Clin Exp Res. 2021;33(4):973-82.

10 Kern KU, Sohns M, Heckes B, Elling C. Tapentadol prolonged release for severe chronic osteoarthritis pain in the elderly: improvements in daily functioning and quality of life. Pain Manag. 2020;10(2):85-95.

11 Aurilio C. Tapentadol prolonged release in fragile geriatric patients > 70 years with chronic severe musculoskeletal pain: an open-label, prospective, observational study. Eur Rev Med Pharmacol Sci. 2019;23(4 Suppl):40-4.

12 Carter GT, Sullivan MD. Antidepressants in pain management. Curr Opin Investig Drugs. 2002;3(3):454-8.

13 Zannikos PN, Smit JW, Stahlberg HJ, Wenge B, Hillewaert VM, Etropolski MS. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects. J Opioid Manag. 2013;9(4):291-300.

14 Biondi DM, Xiang J, Etropolski M, Moskovitz B. Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain. J Opioid Manag. 2015;11(5):393-403.

15 Tzschentke TM, Christoph T, Kögel B, Schiene K, Hennies HH, Englberger W, Haurand M, Jahnel U, Cremers TI, Friderichs E, De Vry J. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007;323(1):265-76.

16 Kneip C, Terlinden R, Beier H, Chen G. Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008;2(1):67-75.
 


Submitted date:
02/24/2023

Accepted date:
10/03/2023

65a6e914a953957e65144152 brjp Articles

BrJP

Share this page
Page Sections